

Author index to Volume 6

- Aastveit TE. *See* Dunsæd CB, 456
 Abbott KL *et al.* Combination chemotherapy for disseminated malignant melanoma, 489
 Abraham T. *See* Nusbaum NJ, 427
 Adams GE. *See* Naylor MA, 259
 Adams M *et al.* Tropisetron alone or in combination with dexamethasone for the prevention and treatment of emesis induced by non-cisplatin chemotherapy: a randomized trial, 514
 Adell R. *See* Sjöholm H, 109
 Aggarwal SK. *See* Palma JP, 311
 Aikou T. *See* Nakamura K, 483
 Ainsworth S. *See* Helson L, 612
 Al-Asfar S. *See* Maki A, 392
 Alberts DS *et al.* Cisplatin-associated neurotoxicity: can it be prevented? 369
 Alberts DS. *See* Brooks DJ, 637
 Al-Katib A. *See* Maki A, 392
 Allegra CJ. *See* Copur S, 154
 Allen PD *et al.* Colorated cell line suppression of lymphokine activated killer cell generation is reversed by suramin, 250
 Anderson H. *See* Adams M, 514
 Andersson A. *See* Zhao R, 657
 Andreotti PE. *See* Cree IA, 398; *also* Kurbacher CM, 697
 Andres E. *See* Maloisel F, 324
 Ang CY. *See* Swaffar DS, 586
 Ardlet C. *See* Dirix L, 53
 Arnold L. *See* Gulliya KS, 545
 Ashizawa T *et al.* Characteristics of the anti-tumor activity of M-16 and M-18, major metabolites of a new mitomycin C derivative KW-2149, in mice, 763
 Au KL. *See* Liang R, 224
 Auburger T. *See* Lemmen P, 744
 Avramis VI. *See* Kees UR, 303
 Ayesb S. *See* Lyubimov E, 727
 Baba H. *See* Yamamoto M, 570
 Bacoyiannis C. *See* Tsavaris N, 599
 Bally MB. *See* Kanter PM, 328
 Barberi-Heyob M *et al.* Addition of heparin 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions, 163
 Barbhaiya RH. *See* Brooks DJ, 637
 Barbieri P. *See* Contu A, 652
 Barley V. *See* Adams M, 514
 Baumgart J. *See* Harstick A, 681
 Beck TM. The pattern of emesis following high-dose cyclophamide and the anti-emetic efficacy of ondansetron, 237
 Bellamy WT *et al.* Cardiotoxicity in the SCID mouse following administration of doxorubicin and cyclosporin A, 736
 Bendix Rabo Y. *See* Zhao R, 657
 Berger DP. *See* Dengler WA, 522
 Bertam J *et al.* Reversal of multiple drug resistance *in vitro* by phosphorothioate oligonucleotides and ribozymes, 124
 Bianco AR. *See* Correale P, 285
 Bissery M-C *et al.* Docetaxel (Taxotere®), a review of preclinical and clinical experience. Part I. Preclinical experience, 339
 Boesen E. *See* Adams M, 514
 Boiocchi M. *See* Gigante M, 479
 Boldt DH. *See* Havlin KA, 229
 Bosanquet N. *See* Johnson N, 243
 Braguer D. *See* Garcia P, 533
 Brett S. *See* Leone L, 604
 Briand C. *See* Garcia P, 533
 Brooks DJ *et al.* Phase I and pharmacokinetic study of etoposide phosphate, 637
 Brown DM. *See* Smith JP, 717
 Brown TD *et al.* A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: a Southwest Oncology Group Study, 219
 Brown TD. *See* Havlin KA, 229
 Bruckner HW. *See* Kurbacher CM, 697
 Brun A. *See* Sjöholm H, 109
 Brysch W. *See* Bertam J, 124
 Bumma C. *See* Leone L, 604
 Bussi P. *See* Leone L, 604
 Cagnola J. *See* Havlin KA, 229
 Campora E. *See* Contu A, 652
 Campos E. *See* Slavutsky I, 758
 Caraglia M. *See* Correale P, 285
 Charles G. *See* Garcia P, 533
 Carpi A. *See* Contu A, 652
 Carr Jr ME *et al.* A sensitive platelet activation-based functional assay for the anti-leukemic agent bryostatin 1, 384
 Carr SL. *See* Carr Jr ME, 384
 Cascinu S *et al.* Escalating dose of tegafur combined with oral etoposide in metastatic gastric carcinoma, 608
 Catalano G. *See* Cascinu S, 608
 Catimel G. *See* Dirix L, 53
 Ceberg C. *See* Sjöholm H, 109
 Chaitchik S. *See* Inbar M, 775
 Chan CH. *See* Liang R, 224
 Chan J. *See* Liang R, 224
 Chan LC. *See* Liang R, 224
 Chan TK. *See* Liang R, 224
 Chapman JM. *See* Hall IH, 147
 Cheshire PJ. *See* Houghton PJ, 317
 Chicoine MR. *See* Silbergeld, 270
 Chiu E. *See* Liang R, 224
 Chorvath B. *See* Sedlak J, 70
 Christensen C. *See* Saunders DE, 562
 Chu E. *See* Copur S, 154
 Chu SI *et al.* Pulmonary toxicity of continuous infusion 5-fluoro-2'-deoxyuridine, 475
 Chu YC. *See* Liang R, 224
 Clavel M. *See* Dirix L, 53
 Clements MK. *See* Daoud SS, 405
 Cole S. *See* Naylor MA, 259
 Colussi AM. *See* Gigante M, 479
 Comandone A. *See* Leone L, 604
 Conroy T. *See* Barberi-Heyob M, 163
 Contu A *et al.* A comparison of the anti-emetic efficacy and safety of intramuscular and intravenous formulations of granisetron in patients receiving moderately emetogenic chemotherapy, 652
 Copur S *et al.* Bone marrow aplasia and severe skin rash after a single dose of methotrexate, 154
 Coria B. *See* Contu A, 652
 Correale P *et al.* Bryostatin 1 enhances lymphokine activated killer sensitivity and modulates the β^1 integrin profile of cultured human tumor cells, 285
 Craig JB. *See* Havlin KA, 229
 Cramer-Giraud U. *See* du Bois A, 645
 Cree IA *et al.* Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay, 398
 Crooks PA. *See* Swaffar DS, 586
 Cufer T *et al.* Cyclosporine A increases serum cortisol levels in rabbits, 615
 Dabut W. *See* Copur S, 154
 Daliani D. *See* Tsavaris N, 599
 Dancy J *et al.* The role of vindesine in oncology — Recommendation after 10 years' experience, 625
 Daoud SS *et al.* Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts, 83; *also* Polymerase chain reaction analysis of cisplatin-induced mitochondrial DNA damage in human ovarian carcinoma cells, 405
 Davey MW. *See* Hargrave RM, 432
 Davey RA. *See* Hargrave RM, 432
 Davies SL. *See* Isaacs RJ, 195
 De Appollonia L. *See* Gigante M, 479

- De Bruijn E. *See* Dirix L, 53
 de Bruijn KM. *See* Adams M, 514
 de Grip WJ. *See* Hofs HP, 277
 Dengler WA *et al.* Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays, 522
 Depenbrock H. *See* Heise H, 686
 Depenni R. *See* Contu A, 652
 Deppe G. *See* Saunders DE, 562
 Desai PB. *See* Swaffar DS, 586
 Dev PK. *See* Nyati MK, 693
 de Valk-Bakker V. *See* Hofs HP, 277
 de Vos D. *See* Hofs HP, 277
 de Vries EGE. *See* van der Graaf WTA, 34
 Dhar S. *See* Liminga G, 578
 Didier A *et al.* Decreased uptake of cyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells and restoration of normal retention by Pgp blockers, 669
 Dirix L *et al.* Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149, 53
 Diwakaran H. *See* Maki A, 392
 Doesburg WH. *See* Hofs HP, 277
 Donati D. *See* Contu A, 652
 Dornish JM. *See* Dunsæd CB, 456
 du Bois A *et al.* Pattern of carboplatin-induced emesis, 645
 Dufour P. *See* Maloïsel F, 324
 Dumortier A. *See* Dirix L, 53
 Dunsæd CB *et al.* Growth inhibition of human tumor xenografts in nude mice by treatment with the antitumor agent 4,6-benzylidene- α -D-glucose (P-1013), 456
 Duraj J. *See* Sedlak J, 70
 Edgren MR. *See* Zhao R, 657
 Egyházi S. *See* Zhao R, 657
 Ellsworth L. *See* Bellamy WT, 736
 Evans SL. *See* Johnson DE, 471
 Evène E. *See* Dirix L, 53
 Fabbrocini A. *See* Correale P, 285
 Falkson CI. Treatment of metastatic malignant melanoma, 709
 Fetouh MI. *See* Daoud SS, 83
 Fieberg HH. *See* Dengler WA, 522
 Filipic B. *See* Cufer T, 615
 Fiola M. *See* du Bois A, 645
 Fleming TR. *See* Brown TD, 219
 Freschi A. *See* Gigante M, 479
 Fridborg H *et al.* Relationship between pharmacokinetic parameters in patients and cytotoxicity *in vitro* of standard and investigational anticancer drugs, 64
 Fukao K. *See* Nozue M, 291
 Fukuzaki H. *See* Nakamura K, 483
 Galligioni E. *See* Gigante M, 479
 Garcia P *et al.* Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses, 533
 Gerli A. *See* Cree IA, 398
 German Ondansetron Study Group. *See* du Bois A, 645
 Gibassier J. *See* Massart C, 135
 Gigante M *et al.* Effect of cyclosporine on teniposide pharmacokinetics and pharmacodynamics in patients with renal cell cancer, 479
 Giovannella BC. *See* Daoud SS, 83
 Glaubitz M. *See* du Bois A, 645
 Goffredo F. *See* Leone L, 604
 Goltzman D. *See* Yu J, 101
 Gomi K. *See* Ashizawa T, 763
 González M. *See* Slavutsky I, 758
 Goodman PJ. *See* Brown TD, 219
 Gorodetsky C. *See* Maloïsel F, 324
 Grant S. *See* Carr Jr ME, 384
 Griffon G *et al.* Comparison of sulforhodamine B, tetrazolium and clonogenic assays for *in vitro* radiosensitivity testing in human ovarian cell lines, 115
 Grindey GB. *See* Houghton PJ, 317
 Grogan TM. *See* Bellamy WT, 736
 Guarrasi R. *See* Correale P, 285
 Gulliya KS *et al.* Relationship of mitochondrial function and cellular adenosine triphosphate levels to pMC540 and merodantoin cytotoxicity in MCF-7 human breast cancer cells, 545
 Gupota RR. *See* Nyati MK, 693
 Gurtler J. *See* Liebmann J, 40
 Hagiwara A. *See* Sakakura C, 553; *also* Tsujimoto H, 438
 Haigh A. *See* Naylor MA, 259
 Hall IH *et al.* Cytotoxicity of imides-N-alkyl semicarbazones, thiosemicarbazones, acetylhydrazones and related derivatives, 147
 Haller U. *See* Koechli OR, 94
 Hanauske A-R. *See* Heise H, 686
 Hand A *et al.* Interferon (IFN)- α and IFN- γ combination with methotrexate: *in vitro* sensitivity studies in four human mesothelioma cell lines, 77
 Hansson J. *See* Zhao R, 657
 Hardy J. *See* Havlin KA, 229
 Hargrave RM *et al.* Development of drug resistance with idarubicin relative to other anthracyclines, 432
 Harman G. *See* Havlin KA, 229
 Harman GS. *See* Abbott KL, 489
 Harris AL. *See* Isaacs RJ, 195
 Harstrick A *et al.* Activity of N-benzyl-adriamycin-14-valerate (AD198), a new anthracycline derivative, in multidrug resistant human ovarian and breast carcinoma cell lines, 681
 Havlin KA *et al.* Deoxyspergualin: phase I clinical, immunologic and pharmacokinetic study, 229
 Heise H *et al.* Characterization and mutual ligand-induced modulation of epidermal growth factor in interferon- α receptors on renal carcinoma cells *in vitro*, 686
 Helson C. *See* Helson L, 612
 Helson L *et al.* Camptothecin cytotoxin effects *in vitro*: dependency on exposure duration and dose, 612
 Hiddenmann W. *See* Bertam J, 124
 Hitoshi A. *See* Ashizawa T, 763
 Hofs HP *et al.* Schedule-dependent enhancement of antitumor activity of ethyldeshydroxy-sparsomycin in combination with classical antineoplastic agents, 277
 Houghton JA. *See* Houghton PJ, 317
 Houghton PJ *et al.* Efficacy of sulofenur and a second generation diarylsulfonylurea, N-[5-(2,3-dihydrobenzofuryl) sulfonyl]-N'-(3,4-dichlorophenyl)urea (LY295501), against colon adenocarcinoma xenografts, 317
 Hua J *et al.* Acidic and neutralized metoclopramide formulation sensitive ionising radiation induced cytotoxicity in human lung adenocarcinoma xenografted to scid mice, 451
 Hudecz F. Design of synthetic branched-chain polypeptides as carriers for bioactive molecules, 171
 Hunakova L. *See* Sedlak J, 70
 Hunter EMM. *See* Cree IA, 398
 Hunter NR. *See* Meyn RE, 443
 Igwemzie LM. *See* Brooks DJ, 637
 Ilanchezhian S *et al.* α -Tocopherol ameliorates cyclophosphamide-induced hyperlipidemia in fibrosarcoma-bearing rats, 771
 Imanishi T. *See* Sakakura C, 553; *also* Tsujimoto H, 438
 Inbar M *et al.* Carboplatin-related idiosyncrasy, 775
 International Casodex Study Group. *See* Lunglmayr G, 508
 Isaacs RJ *et al.* Topoisomerases II α and β as therapy targets in breast cancer, 195
 Iwaguchi T. *See* Shimizu M, 158
 Jenner T. *See* Naylor MA, 259
 John WJ. *See* Swaffar DS, 586
 Johnson DE *et al.* The growth inhibitory properties of a dopamine agonist (SKF 38393) on MCF-7 cells, 471
 Johnson N *et al.* Cost effectiveness of 5-hydroxytryptamine₂ receptor antagonists: a retrospective comparison of ondansetron and granisetron, 243
 Johnston DH. *See* Allen PD, 250
 Joossens E. *See* Dirix L, 53
 Jordan VC. *See* Tonetti DA, 498
 Junggren KL. *See* Sjöholm H, 109
 Kaddurah-Daouk R. *See* Martin KJ, 419
 Kanekal S. *See* Smith JP, 717
 Kanter PM *et al.* Reply to Madewell and Kraegel, 328
 Kanter PM. *See* Klaich GM, 45

- Kasai M. *See* Ashizawa T, 763
 Kataoka T. *See* Shimizu M, 158
 Katsikas M. *See* Tsavaris N, 599
 Kaul S. *See* Brooks DJ, 637
 Kees UR *et al.* Biochemical pharmacology and DNA methylation studies of arabinosyl 5-azacytidine and 5,6-dihydro-5-azacytidine in two human leukemia cell lines PER-145 and PER-163, 303
 Kerbel RS. *See* Rak JW, 3
 Kidman AD. *See* Hargrave RM, 432
 Killian M. *See* Bertam J, 124
 Kim HJ. *See* Chu SI, 475
 King JM. *See* Kanter PM, 328
 Klaich GM *et al.* Characterization of a monoclonal antibody recognizing a 138 kDa glioblastoma-associated antigen, 45
 Kneba M. *See* Bertam J, 124
 Kobayashi S. *See* Ashizawa T, 763
 Koehli OR *et al.* *In vitro* chemosensitivity of paclitaxel and other chemotherapeutic agents in malignant gestational trophoblastic neoplasms, 94
 Koehler PJ. Use of corticosteroids in neuro-oncology, 19
 Koeller J. *See* Havlin KA, 229
 Koler I. *See* Dirix L, 53
 Kono A. *See* Matsuoaka H, 413
 Kosmas C. *See* Tsavaris N, 599
 Kosmidis P. *See* Tsavaris N, 599
 Kraegel SA. *See* Madewell BR, 327
 Krebs D. *See* Kurbacher CM, 697
 Kremer R. *See* Yu J, 101
 Kuhn JG. *See* Havlin KA, 229
 Kumano-hoso T. *See* Nakamura K, 483
 Kurbacher CM *et al.* *In vitro* activity of titanocenedichloride versus cisplatin in four ovarian carcinoma cell lines evaluation by a microtiter plate ATP bioluminescence assay, 697
 Kurbacher JA. *See* Kurbacher CM, 697
 Kurtz JE. *See* Maloisel F, 324
 Kusumoto T. *See* Yamamoto M, 570
 Kuwano M. *See* Yamamoto M, 570
 Kwong YL. *See* Liang R, 224
 Lan L-B. *See* Lyubimov E, 727
 Larripa I. *See* Slavutsky I, 758
 Larsson R. *See* Fridborg H, 64; *also* Liminga G, 578
 Lavelle F. *See* Bissery M-C, 339
 Lawrence WD. *See* Saunders DE, 562
 Leclech G. *See* Massart C, 135
 Lemmen P *et al.* Uptake and distribution of the boron-containing ether lipid B-Et-11-OMe in tumor-bearing mice, 744
 Leone L *et al.* Stability of ifosfamide in solution for multiday infusion by external pump, 604
 Lewin F *et al.* The effect of 5-fluorouracil on cisplatin induced DNA interstrand cross-linking in a mouse ascites tumor growing *in vivo*, 465
 Liang R *et al.* Intensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantrone, 224
 Lie A. *See* Liang R, 224
 Liebmann J *et al.* Combination intraventricular therapy with thiotepa and catarabine in meningeal carcinomatosis due to breast cancer: *in vitro* evidence for supra-additive cytotoxicity, 40
 Liminga G *et al.* Cytotoxic effect of calcein acetoxymethyl ester on human tumor cell lines: drug delivery by intracellular trapping, 578
 Linder S. *See* Zhao R, 657
 Linnainmaa K. *See* Hand A, 77
 Liu H-W. *See* Gulliya KS, 545
 Loo F. *See* Didier A, 669
 Lucas C. *See* Massart C, 135
 Lunglmayr G *et al.* Efficacy and tolerability of Casodex in patients with advanced prostate cancer, 508
 Lutz L. *See* Houghton PJ, 317
 Lyubimov E *et al.* Saturation reversal of the multidrug pump using many reversers in low-dose combinations, 727
 Macdonald JS. *See* Brown TD, 219
 Macey MG. *See* Allen PD, 250
 McKinney LM. *See* Brooks DJ, 637
 McMillan TJ. *See* Valenzuela MT, 749
 Madewell BR *et al.* Re: "Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs", 327
 Madsen CL. *See* Silbergeld, 270
 Maehara Y. *See* Yamamoto M, 570
 Maestri A. *See* Contu A, 652
 Maki A *et al.* The *bcl-2* and *p53* oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma, 392
 Maloisel F *et al.* Platin salts-induced hemolytic anemia: cisplatin- and the first case of carboplatin-induced hemolysis, 324
 Malone JM. *See* Saunders DE, 562
 Malviya VK. *See* Saunders DE, 562
 Marchal C. *See* Griffon G, 115
 Marone G. *See* Correale P, 285
 Martin KJ *et al.* Microtubule stabilization and potentiation of taxol activity by the creatine analog cyclocreatine, 419
 Massart C *et al.* Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line, 135
 Matsuoaka H *et al.* Cytotoxicity of CPT-11 for gastrointestinal cancer cells cultured on fixed-contact-sensitive plates, 413
 Matthews JL. *See* Gulliya KS, 545
 Mattson K. *See* Hand A, 77
 Mayer LD. *See* Kanter PM, 328
 Meriggi F. *See* Contu A, 652
 Merimsky O. *See* Inbar M, 775
 Merlin J-L. *See* Griffon G, 115; *also* Barberi-Heyob M, 163
 Mertelsmann R. *See* Dengler WA, 522
 Meyn RE *et al.* Apoptosis in murine tumors treated with chemotherapy agents, 443
 Milas L. *See* Meyn RE, 443
 Mini E. *See* Cree IA, 398
 Mohammad RM. *See* Maki A, 392
 Mulder NH. *See* van der Graaf WTA, 34
 Myers L. *See* Houghton PJ, 317
 Nakamura K *et al.* Controlled release of poly-D, L-lactic acid containing bleomycin, 483
 Natsugoe S. *See* Nakamura K, 483
 Naylor MA *et al.* Fused pyrazine mono-N-oxides as bioreductive drugs III. Characterization of RB 90740 *in vitro* and *in vivo*, 259
 Nesland JM. *See* Dunsæd CB, 456
 Nethersell ABW. *See* van der Graaf WTA, 34
 Newlands AC. *See* Allen PD, 250
 Nilsson K. *See* Liminga G, 578
 Nishida M. *See* Nozue M, 291
 Noel JK. *See* Alberts DS, 369
 Nohynek G. *See* Bissery M-C, 339
 Novotny L. *See* Sedlak J, 70
 Nozue M *et al.* Selection of three out of 24 anti-cancer agents in poorly-differential gastric cancer cell lines, evaluation by the AUC/IC₅₀ ratio, 291
 Núñez MI. *See* Valenzuela MT, 749
 Nusbaum NJ *et al.* Paclitaxel effect on a leukemia cell line: importance of paclitaxel concentration, 427
 Nyati MK *et al.* Evaluation of certain ureas and nitrosoureas of 2,3-dihydro-1,4-benzothiazines against Sarcoma-180 solid tumor *in vivo*, 693
 Nygren P. *See* Fridborg H, 64; *also* Liminga G, 578
 Oberling F. *See* Maloisel F, 324
 Ochieng J. *See* Johnson DE, 471
 Odeleye A. *See* Bellamy WT, 736
 Ogaki M. *See* Sakakura C, 553
 Oh-Hashi F. *See* Shimizu M, 158
 Ohgaki M. *See* Tsujimoto H, 438
 Ohyama T. *See* Tsujimoto H, 438
 Okabe M. *See* Ashizawa T, 763
 Okamoto A. *See* Ashizawa T, 763
 Olea N. *See* Valenzuela MT, 749
 Oliva C. *See* Leone L, 604
 Olsson A. *See* Hua J, 451
 Omeo N. *See* Contu A, 652
 Orenberg EK. *See* Smith JP, 717
 O'Rourke T. *See* Brown TD, 219
 Osaki K. *See* Tsujimoto H, 438
 Ottenheim HCJ. *See* Hofs HP, 277
 Oyama T. *See* Sakakura C, 553
 Ozaki K. *See* Sakakura C, 553

- Pajk B. *See* Cufer T, 615
 Palfner K. *See* Bertam J, 124
 Palma JP *et al.* Cisplatin and carboplatin mediated activation of murine peritoneal macrophages *in vitro*: production of interleukin-1 α and tumor necrosis factor- α , 311
 Papavasiliou V. *See* Yu J, 101
 Pashinsky I. *See* Lyubimov E, 727
 Patella V. *See* Correale P, 285
 Pazzagli M. *See* Cree IA, 398
 Pedraza V. *See* Valenzuela MT, 749
 Pelin K. *See* Hand A, 77
 Peng YM. *See* Bellamy WT, 736
 Pepe S. *See* Correale P, 285
 Pero RW. *See* Hua J, 451
 Perras JP. *See* Koehli OR, 94
 Pettersen EO. *See* Dunsæd CB, 456
 Pettit S. *See* Maki A, 392
 Pfeifer M. *See* Cufer T, 615
 Phillips J. *See* Havlin KA, 229
 Pinto A. *See* Correale P, 285
 Pinzani P. *See* Cree IA, 398
 Piro S. *See* Contu A, 652
 Pourquier P. *See* Massart C, 135
 Probst T. *See* Lemmen P, 744
 Provè A. *See* Dirix L, 53
 Pugh PR. *See* Brown TD, 219
 Punt CJA *et al.* Spontaneous fracture of implanted central venous catheters in cancer patients, report of two cases and retrospective analysis of the 'pinch-off sign' as a risk factor, 594
 Rajoria CM. *See* Nyati MK, 693
 Rak JW *et al.* Consequences of angiogenesis for tumor progression, metastasis and cancer therapy, 3
 Randolph J. *See* Brooks DJ, 637
 Raoul M. *See* Massart C, 135
 Rastetter JW. *See* Heise H, 686
 Redman B. *See* Maki A, 392
 Rhim J. *See* Yu J, 101
 Ringborg U. *See* Lewin F, 465
 Riva E. *See* Contu A, 652
 Robert J. *See* Massart C, 135
 Robertson N. *See* Naylor MA, 259
 Rode B. *See* Cufer T, 615
 Rodriguez M. *See* Koehli OR, 94
 Rosenthal GA. *See* Swaffar DS, 586
 Rüfenacht E. *See* Adams M, 514
 Ruíz de Almodóvar JM. *See* Valenzuela, 749
 Sabbatini R. *See* Contu A, 652
 Sachdanandam P. *See* Ilanchezhian S, 771
 Saito H. *See* Ashizawa T, 763
 Saito T. *See* Matsuoka H, 413
 Sakaguchi Y. *See* Yamamoto M, 570
 Sakaibara T. *See* Sakakura C, 553
 Sakakibara T. *See* Tsujimoto H, 438
 Sakakura C *et al.* Inhibition of colon cancer cell proliferation by antisense oligonucleotides targeting messenger RNA of the Ki-ras gene, 553
 Sakakura C. *See* Tsujimoto H, 438
 Sakelaaropoulos N. *See* Tsavaris N, 599
 Sakuyama A. *See* Tsujimoto H, 438
 Salford LG. *See* Sjöholm H, 109
 Sanderink G-J. *See* Bissery M-C, 339
 Sandrin A. *See* Gigante M, 479
 Sasirekha S. *See* Ilanchezhian S, 771
 Saß G. *See* Kurbacher CM, 697
 Saunders DE *et al.* Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D₃ combined with retinoic acid or dexamethasone, 562
 Schacter L. *See* Brooks DJ, 637
 Schaer GN. *See* Koehli OR, 94
 Schenk V. *See* Koehli OR, 94
 Scheulen ME. *See* Harstrick A, 681
 Schleucher N. *See* Harstrick A, 681
 Schlingensiepen K-H. *See* Bertam J, 124
 Schriuees D. *See* van Oosterom AT, 356
 Schrijvers D. *See* Dirix L, 53
 Schroeder J. *See* Harstrick A, 681
 Schulte J. *See* Dengler WA, 522
 Sedlak J *et al.* Effects of protein kinase C inhibitor, staurosporine derivatives CGP 41 251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines, 70
 Seeber S. *See* Harstrick A, 681
 Seo Y. *See* Matsuoka H, 413
 Sevin B-U. *See* Koehli OR, 94
 Sharma R. *See* Gulliia KS, 545
 Sheng Y. *See* Hua J, 451
 Shimizu M *et al.* *In vitro* and *in vivo* anti-tumor activity of the interferon inducer bropirimine, 158
 Shimotsuma M. *See* Tsujimoto H, 438
 Shinkawa T. *See* Nakamura K, 483
 Shirasu M. *See* Tsujimoto H, 438
 Siemann D. *See* Naylor MA, 259
 Sikic BI. *See* Cufer T, 615
 Silbergeld DL *et al.* *In vitro* assessment of Taxol for human glioblastoma: chemosensitivity and cellular locomotion, 270
 Siles E. *See* Valenzuela MT, 749
 Silingardi V. *See* Contu A, 652
 Sjöholm H *et al.* Necrosis of malignant gliomas after intratumoral injection of ²⁰¹Tl *in vivo* in the rat, 109
 Skog S. *See* Lewin F, 465
 Skrk J. *See* Cufer T, 615
 Skubitz KM. *See* Chu SI, 475
 Slavutsky I *et al.* Micronuclei induction by carboplatin in human lymphocyte subpopulations, 758
 Small CL. *See* Daoud SS, 405
 Smith JP *et al.* Intratumoral chemotherapy with a sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts, 717
 Sorio R. *See* Gigante M, 479
 Soukop M. *See* Adams M, 514
 Srinivas NR. *See* Brooks DJ, 637
 St Croix BD. *See* Rak JW, 3
 Stein WD. *See* Lyubimov E, 727
 Stephens LC. *See* Meyn RE, 443
 Stephens MA. *See* Naylor MA, 259
 Steren A. *See* Koehli OR, 94
 Steward WP. *See* Dancey J, 625
 Stock E. *See* Smith JP, 717
 Strand S-E. *See* Sjöholm H, 109
 Stratford IJ. *See* Naylor MA, 259
 Strijk S. *See* Punt CJA, 594
 Sugimachi K. *See* Yamamoto M, 570
 Sutherland LA. *See* Cree IA, 398
 Swaffar DS *et al.* Combination therapy with 5-fluorouracil and L-canavanine: *in vitro* and *in vivo* studies, 586
 Tagliaferri P. *See* Correale P, 285
 Takahashi T. *See* Sakakura C, 553; *also* Tsujimoto H, 438
 Takiguchi S. *See* Matsuoka H, 413
 Talamini R. *See* Gigante M, 479
 Tanaka M. *See* Nozue M, 291
 Tateo S. *See* Contu A, 652
 Teicher BA. *See* Martin KJ, 419
 Tentas K. *See* Tsavaris N, 599
 Thangaraju M. *See* Ilanchezhian S, 771
 Thomas DA. *See* Swaffar DS, 586
 Thomas T. *See* Brooks DJ, 637
 Thomssen C. *See* du Bois A, 645
 Todoroki T. *See* Nozue M, 291
 Toffoli G. *See* Gigante M, 479
 Tomida A. *See* Tsuruo T, 213
 Tomoda H. *See* Matsuoka H, 413
 Tonetti DA *et al.* Possible mechanisms in the emergence of tamoxifen-resistant breast cancer, 498
 Toth J. *See* Houghton PJ, 317
 Trask CW. *See* Adams M, 514
 Tribukait B. *See* Lewin F, 465
 Tsavaris N *et al.* 5-fluorouracil, folinic acid and cisplatin in advanced colorectal cancer: a pilot study, 599
 Tsujimoto H *et al.* Therapeutic effects of the antiangiogenesis inhibitor TNP-470 against carcinomatous peritonitis in mice, 438
 Tsujimoto H. *See* Sakakura C, 553
 Tsukagoshi S. *See* Shimizu M, 158
 Tsuruo T *et al.* Multidrug resistance, 213
 Untch M. *See* Koehli OR, 94
 Vach W. *See* du Bois A, 645
 Valenzuela MT *et al.* Relationship between doxorubicin cell sensitivity, drug-induced DNA double-strand breaks, glutathione content and P-glycoprotein in mammalian tumor cells, 749
 van der Graaf WTA *et al.* *In vitro* and *in vivo* studies on the action of BW502U83, an arylmethylaminopropanediol, 34
 van der Hoeven JJM. *See* Punt CJA, 594
 van de Sluis R. *See* Punt CJA, 594
 Vanhoefer U. *See* Harstrick A, 681
 van Oosterom AT *et al.* Docetaxel (Taxotere®), a review of preclinical and clinical experience. Part II. Clinical experience, 356

- van Oosterom A. *See* Dirix L, 53
 van Rennes H. *See* Hofs HP, 277
 Vassallo CD. *See* Martin KJ, 419
 Verhagen CAH. *See* Punt CJA, 594
 Vigneron M. *See* Barberi-Heyob M, 163
 Villalobos M. *See* Valenzuela MT, 749
 Von Hoff DD. *See* Havlin KA, 229
 Vrhovec I. *See* Cufer T, 615
- Wagener DJTh. *See* Hofs HP, 277
 Wappler NL. *See* Saunders DE, 562
 Watanabe N. *See* Tsujimoto H, 438
 Weinstein RS. *See* Bellamy WT, 736
 Weiss GR. *See* Havlin KA, 229
 Weißfloch L. *See* Lemmen P, 744
 Wells N. *See* Isaacs RJ, 195
- Wenger J. *See* Didier A, 669
 Wilke H. *See* Harstrick A, 681
 Williams JR. *See* Saunders DE, 562
 Williams NS. *See* Allen PD, 250
 Wong KF. *See* Liang R, 224
 Wong OT. *See* Hall IH, 147
- Xu MJ. *See* Bellamy WT, 736
- Yamada K. *See* Nakamura K, 483
 Yamamoto M *et al.* Cyclosporin A and FK506 reverse anthracycline resistance by altering the cell cycle, 570
 Yamazaki J. *See* Sakakura C, 553; *also* Tsujimoto H, 438
- Yano K. *See* Matsuoka H, 413
 Yeung YM. *See* Liang R, 224
 Yosef H. *See* Adams M, 514
 Yu J *et al.* Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia, 101
 Yu NY. *See* Smith JP, 717
- Zakotnik B. *See* Cufer T, 615
 Zaniboni A. *See* Contu A, 652
 Zhao R *et al.* Apoptosis and *c-jun* induction by cisplatin in a human melanoma cell line and a drug-resistant daughter cell line, 657
 Zijistra JG. *See* van der Graaf WTA, 34

Keyword index to Volume 6

- Acetylhydrazones, 147
 Acute myeloid leukemia, 224
 AD 198, 681
 Adenocarcinoma, 451
 Adrenal cortex hormones, 19
 Advanced colorectal cancer, 219, 599
 Afenocarcinoma, 317
 Alkylation, 693
 AML, 432
 Analog, 53, 101
 Anemia, 324
 Angiogenesis, 3
 inhibitor, 438
 Antiandrogen, 508
 Anticancer, 693
 agents, 64
 Antiemetic, 243, 652
 Antiestrogenic, 471
 Antineoplastic agents, 277
 Antiproliferative, 471
 Antisense, 124
 phosphorothioate oligo-nucleotides, 553
 -mediated change, 553
 Antitumor
 agent, 171
 effect, 158
 efficacy, 339
 Apoptosis, 443, 657
 Arylmethylaminopropanediol, 34
 AT17, 744
 ATP, 398, 545
 assay, 94
 bioluminescence assay, 697
 Auger electrons, 109

 β 1 integrins, 285
 B cell, 392
bcl-2, 392
 B-Et-OMe, 744
 1,4-benzothiazine, 693
 Benzylidene-glucose, 456
 Bicalutamine, 508
 Biodynamics, 339
 Bioreductive drugs, 259
 Bleomycin, 483
 BNCT, 744
 Bone marrow transplantation, 489
 Boron neutron capture therapy, 744

 Brain
 edema, 19
 neoplasms, 19
 tumor, 109
 Branched-chain polypeptide, 171
 Breast
 cancer, 40, 195, 498, 545, 681
 carcinoma, 83
 neoplasms, 562
 Bropiramine, 158
 Bryostatin 1, 285, 384, 392
 Buthionine sulfoximine, 697
 BW502U83, 34

 C3H mice, 744
 Calcein/AM, 578
 Calcitriol, 562
 β -Camera, 109
 Camptothecin, 83, 612
 L-Canavanine, 586
 Cancer therapy, 3
 Carboplatin, 311, 324, 645, 758, 775
 Carborane, 744
 Carcinomatous peritonitis, 438
 Carrier, 171
 Casodex (ICI 176,334), 508
 Cell
 cycle, 70
 lines, 303
 locomotion, 270
 sensitivity, 749
 Central venous catheters, 594
 CGP 41 251, 70
 Chemiluminescence, 398
 Chemosensitivity, 270
 testing, 94, 291, 522
 Chemotherapy, 195, 398, 443, 475, 489, 594, 625, 727
 CI 980, 533
 Cisplatin, 291, 311, 324, 369, 405, 465, 599, 657, 697
 Cisplatinum, 489
c-jun, 657
 Clonogenic assay, 115
 Colon, 317
 cancer, 553
 Combination, 533
 chemotherapy, 277, 419, 586
 Conjugate, 171
 Cortisol, 615
 Cost-benefit analysis, 243

 Creatine kinase, 419
 Cross-linking, 465
 Cyclocreatine, 419
 Cyclophosphamide, 237, 771
 Cyclosporine, 479
 Cyclosporin(e) A, 135, 570, 615, 669
 Cytarabine, 40
 Cytotoxicity, 147, 578
 assay, 522

 Dabarbazine, 489
 Degradable poly-D,L-lactic acid, 483
 Deoxyspergualin, 229
 Deuterated benzaldehyde, 456
 Dexamethasone, 19, 514, 562
 Diffuse large cell lymphoma, 392
 DNA
 damage, 657
 methylation, 303
 strand breaks, 34, 259
 synthesis, 70
 Docetaxel, 339, 533
 Dolastatin
 10, 392
 15, 392
 Dopamine agonists, 471
 Doxorubicin, 135, 749
 -induced DNA double-strand breaks, 749
 Drug
 accumulation, 727
 resistance, 70, 195

 Economics, 243
 Emesis, 237, 514
 Epidermal growth factor, 686
 Etoposide
 phosphate, 637
 sensitization, 432
 Extravasation of chemotherapy, 594

 Fibrosarcoma, 771
 FK506, 570
 Flow cytometry, 70
 Fluorescence assay, 522
 5-fluoro-2'-deoxyuridine, 475
 5-fluorouracil, 219, 465, 586, 599

 Folinic acid, 599
 Fracture, 594
 Freeze-fracture, 83

 Gastric
 cancer cells, 291
 carcinoma, 608
 Gene regulation *Ki-ras*, 553
 Gestational trophoblastic neoplasms, 94
 Glioblastoma, 270
 multiforme, 45
 Gliomas, 109
 Granisetron, 243, 652
 Growth inhibition, 456

 Hemolysis, 324
 HT-29, 612
 5-HT₃ receptor antagonist, 514
 Human
 leukemia, 303
 malignant mesothelioma, 77
 tumor cell lines, 578
 tumor cells, 285
 Hypercalcemia, 101
 Hypersensitivity, 154
 Hypoxia, 259

 ICP-AES, 744
 ICP-MS, 744
 Idarubicin, 432
 Idiosyncrasy, 775
 Ifosfamide, 604
 IL-1 α , 311
 IL-2, 250
 Infusion, 604
 Infusional chemotherapy, 475
 Interferon, 686
 - α , 77
 - β , 77
 - γ , 77
 inducer, 158
 Intra-arterial treatment, 34
 Intramuscular, 652
 Intratumoral drug delivery, 717
In vitro, 432
 assay, 64
 testing, 77
 Isobolograms, 562

- K-562 leukemia cells, 70
KW-2149, 53, 763
- L1210 mouse leukemia, 70
Leukemia, 427, 625
Lipids, 771
Liposomes, 83
Luciferase, 398
Lung cancer, 625
LY295501, 317
Lymphokine activated killer, 285
Lymphoma, 625
- MAC method, 759
Macrophage activation, 311
Mammary carcinoma, 744
MDR, 479, 681, 736
 reversing agent, 213
MDRI, 612
Mechanisms of action, 237, 339
Medullary carcinoma of thyroid, 135
Melanoma, 83, 489, 625
 cells, 657
Meninges, 40
Merocyanine 540, 545
Merodantoin, 545
Metabolite, 763
Metastasis, 3
Metastatic malignant melanoma, 709
Methotrexate, 77, 154, 398
Metoclopramide, 451
MLA PaCa-2, 586
Micronucleus, 758
Microtubule(s), 419, 533
Mitochondria, 545
Mitochondrial DNA, 405
Mitomycin C, 53, 763
Mitoxantrone, 224
Modulation, 686
Monoclonal antibody, 45, 213
Motility, 270
MS-209, 213
MTT assay, 115
Multi(ple)drug resistance, 124, 135, 432, 570, 669, 727
- Multiple myeloma, 736
Murine tumors, 277
Mutagenesis, 758
- N-oxides, 259
Nausea, 645
Neurotoxicity, 369
Nitrosourea, 693
Non-cisplatin chemotherapy, 514
Nucleoside analogs, 303
Nude mice, 456
- Oligonucleotides, 124
Ondansetron, 237, 243, 645
Oral etoposide, 608
Osteosarcoma, 744
Ovarian
 cancer, 405, 681
 carcinoma, 697
 carcinoma A2780 cells, 70
 neoplasms, 562
 tumor, 115
OVCAR-3, 612
- p53, 392
Paclitaxel, 94, 427
Pancreatic
 cancer, 717
 carcinoma, 586
Pancytopenia, 154
P-glycoprotein, 124, 432, 615, 669
Pharmacokinetics, 53, 64, 229, 427, 637
Phase
 I/I, 53, 637
 I trial, 229
 II-III trial, 219
Phenothiazine, 693
Pinch-off sign, 594
Pirarubicin, 291
Placental site trophoblastic tumor, 94
Platelet
 activation, 384
- Platelet (*contd.*)
 aggregation, 384
 secretion, 384
Polymer, 483
Prevention, 369
Prolactin, 471
Proliferation assay, 522
Propidium iodide, 522
Prostate cancer, 508
Protein
 kinase C, 384
 kinase inhibitors, 70
 synthesis inhibitor, 277
PSC-833, 213
Pulmonary toxicity, 475
Pump, 604
- Quantitative polymerase chain reaction, 405
- Radiosensitivity, 115, 451
Randomized trial, 514
Rash, 154
Reductive activation, 259
Renal
 carcinoma, 686
 cell cancer, 475, 479
Resistance, 339, 498
Retinoic acid, 562
Reversal, 727
Ribozymes, 124
RP 56076, 339
- S9788, 135
Sarcoma-180, 693
SCID mouse/mice, 451, 736
SDZ PSC 833, 669
Semicarbazones, 147
SK-N-AS, 612
SK-N-FI, 612
SN-38, 291
Solid form PLA, 483
Sparsomycin, 277
Spinal cord compression, 19
Squamous cancer, 101
- SRB assay, 115
Stability, 604
Staurosporine, 70
Sulofenur, 317
Suppressor factor, 250
Suramin, 250
Synergism, 277
- Tamoxifen, 498
Taxol, 270, 419, 427
Taxotere®, 339
Tegafur, 608
Teniposide, 479
Thallium, 109
Thiosemicarbazones, 147
Thiotepa, 40
Titanocenedichloride, 697
TNP-470, 438
 α -Tocopherol, 771
Topoisomerase, 195
Toxicity, 324, 775
Toxicology, 339
Treatment, 709
Trimetrexate, 219
Tropisetron, 514
Tubulin, 533
Tumor, 443
 growth, 451
 necrosis factor- α , 311
 progression, 3
- U373-MG, 612
Ultrastructure, 545
- VA-ES-BJ, 612
Valinomycin, 405
Verapamil, 135, 291
Vindesine, 625
Vitamin D, 101
Vomiting, 645
- Xenograft(s), 317, 456
ZR-75-1, 612